SCHEMBL8096053

SCHEMBL8096053

CCCCCCC(NC(C)=O)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD1 Q9Y239 3/20 0.60
SIRT6 Q8N6T7 1/20 0.56
SIRT1 Q96EB6 1/20 0.56
GPR84 Q9NQS5 3/20 0.52
MAPT P10636 2/20 0.52
KDM4E B2RXH2 1/20 0.52
THRB P10828 1/20 0.52
ALOX15 P16050 1/20 0.52
NFKB1 P19838 1/20 0.52
PTGS2 P35354 1/20 0.52
THPO P40225 1/20 0.52
RECQL P46063 1/20 0.52
BLM P54132 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
FFAR1 O14842 1/20 0.52
SLC6A5 Q9Y345 2/20 0.51
GNPAT O15228 1/20 0.50
ALDH1A1 P00352 1/20 0.50
LCK P06239 1/20 0.50
PPARD Q03181 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10599969 1.00 NOD1 (0.60) NOD1SIRT6SIRT1GPR84MAPT
SCHEMBL10602700 1.00 NOD1 (0.60) NOD1SIRT6SIRT1GPR84MAPT
SCHEMBL4609045 1.00 NOD1 (0.60) NOD1SIRT6SIRT1GPR84MAPT
SCHEMBL10603409 1.00 NOD1 (0.60) NOD1SIRT6SIRT1GPR84MAPT
SCHEMBL10599977 1.00 NOD1 (0.60) NOD1SIRT6SIRT1GPR84MAPT
SCHEMBL5982247 1.00 NOD1 (0.60) NOD1SIRT6SIRT1GPR84MAPT
SCHEMBL10600983 1.00 NOD1 (0.60) NOD1SIRT6SIRT1GPR84MAPT
SCHEMBL10599643 1.00 NOD1 (0.60) NOD1SIRT6SIRT1GPR84MAPT
SCHEMBL10603414 1.00 NOD1 (0.60) NOD1SIRT6SIRT1GPR84MAPT
SCHEMBL21801849 1.00 NOD1 (0.60) NOD1SIRT6SIRT1GPR84MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3865591-B1 SET OF BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME CARDIOMIX S R L (IT) 2024-04-03 EP claimed
US-20230080158-A1 SET OF BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME CARDIOMIX S.R.L. (IT) 2023-03-16 US claimed
US-20220208386-A1 DIAGNOSTIC FOR MATERNAL RISK OF HAVING A CHILD WITH AUTISM SPECTRUM DISORDER ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2022-06-30 US claimed
US-20220118269-A1 MONITORING EFFICACY OF MAGNETIC AND ELECTRIC FIELDS USING BIOMARKERS UNIVERSITY OF IOWA RESEARCH FOUNDATION 2022-04-21 US claimed
EP-3947732-A2 DIAGNOSTIC FOR MATERNAL RISK OF HAVING A CHILD WITH AUTISM SPECTRUM DISORDER Arizona Board of Regents on behalf of Arizona State University (US) 2022-02-09 EP claimed
WO-2021161208-A1 SET OF BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME CARDIOMIX S.R.L. (IT) 2021-08-19 WO claimed
EP-3865591-A1 SET OF BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME Cardiomix S.r.l. (IT) 2021-08-18 EP claimed
US-20260076944-A1 COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH UNIV CALIFORNIA (US) 2026-03-19 US disclosed
US-20250375505-A1 COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM UNIV CALIFORNIA (US) 2025-12-11 US disclosed
US-20250258146-A1 QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP HUMAN METABOLOMICS INSTITUTE INC. (CN) 2025-08-14 US disclosed
EP-3865591-B1 SET OF BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME CARDIOMIX S R L (IT) 2024-04-03 EP disclosed
US-11850440-B2 Therapeutic systems using magnetic fields UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2023-12-26 US disclosed
US-20230091156-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING ARTHRITIS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2023-03-23 US disclosed
US-20220102000-A1 PREDICTING BLOOD METABOLITES YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2022-03-31 US disclosed
EP-3947732-A2 DIAGNOSTIC FOR MATERNAL RISK OF HAVING A CHILD WITH AUTISM SPECTRUM DISORDER Arizona Board of Regents on behalf of Arizona State University (US) 2022-02-09 EP disclosed
WO-2021161208-A1 SET OF BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME CARDIOMIX S.R.L. (IT) 2021-08-19 WO disclosed
EP-3865591-A1 SET OF BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME Cardiomix S.r.l. (IT) 2021-08-18 EP disclosed
US-20210052910-A1 THERAPEUTIC SYSTEMS USING MAGNETIC FIELDS UNIVERSITY OF IOWA RESEARCH FOUNDATION 2021-02-25 US disclosed
EP-0973710-A2 OMEGA-AMINO ACID DERIVATIVES, PROCESSES OF THEIR PREPARATION AND THEIR USE Bochemie S.R.O. (CZ) 2000-01-26 EP disclosed
WO-1998045233-A2 OMEGA-AMINO ACID DERIVATIVES, PROCESSES OF THEIR PREPARATION AND THEIR USE BOCHEMIE S.R.O. (CZ) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250375505-A1 COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM CYP27A1, LIPC, CYP46A1 NOD1 3025/4885SIRT6 2548/4885SIRT1 1869/4885
US-20260076944-A1 COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH IDO1, INMT, IDO2 NOD1 3811/4885SIRT6 789/4885SIRT1 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.